ClearPoint Neuro Highlights Partner Aspen Neuroscience’s RMAT Designation From FDA For Parkinson’s Therapy, Sasineprocel
RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease.SOLANA BEACH, CA / ACCESS Newswire / July 31,
ClearPoint's partner company got special permission from the FDA to test a new Parkinson's medicine faster. This is a good sign that doctors and the FDA think the treatment might really help sick people.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.